Bruntwood SciTech Agrees Landmark Deal With Cellular Origins at Melbourn Science Park

Bruntwood SciTech – a joint venture between Bruntwood, L&G and Greater Manchester Pension Fund – has announced a significant lease agreement for the Da Vinci Building at Melbourn Science Park in Cambridge. 

Cellular Origins, a leader in automated cell therapy manufacturing at scale, has taken all 41,000 sq ft to establish its new global headquarters following its Series A raise and rapid growth. Previously occupied by AstraZeneca, the new location places Cellular Origins at the heart of the UK’s R&D ‘Golden Triangle’, providing it with unrivalled access to world-class research and talent. 

Cell therapies are transformative treatments, but their widespread adoption is currently limited by extremely high manufacturing costs, with labour accounting for more than half of cost of goods. Cellular Origins is addressing this by combining mobile robotics, automation and AI with proven bioprocess technologies to industrialise cell therapy manufacturing at scale. It was recently awarded ISO certification, demonstrating operational maturity and readiness to support commercial-scale manufacturing. 

Its expanded headquarters at Melbourn Science Park will provide the business with a world leading combined robotics and biological facility. The space will support the development and deployment of its automated manufacturing platform, Constellation, and the delivery of commercial-scale cell therapy manufacturing systems to customers. The move will also allow for significant expansion plans – including the doubling of its workforce – and further enhance its collaboration with global partners, including leading instrument providers, and cell therapy manufacturers Johnson & Johnson. 

Cellular Origins is a spin-out of UK technology consultancy TTP, which has been established in the Park since 1987.

Melbourn Science Park is located just 20 minutes from Cambridge, under an hour from London, and close to multiple international airports, allowing for excellent connectivity to other centres of research excellence nationally and globally. It combines these links with a peaceful, green setting spread across 17 acres of landscaped grounds, providing space to think, connect and recharge. 

With close links to world-class research and talent, alongside flexible, serviced and leased offices and labs, it is a place designed to support innovation and ambition. 

Edwin Stone, CEO at Cellular Origins said: “Securing the Da Vinci building as our new headquarters marks an important step in building Cellular Origins’ long term growth. Following a successful Series A raise in November 2025, this step allows us to create the right foundations, not just in technology, but in infrastructure, culture and capability to support our ambition to scale cell therapy manufacturing. As a spin-out from TTP, it’s particularly meaningful for us to continue our growth on Melbourn Science Park. This facility represents the kind of company we are building: one designed for scale, grounded in engineering excellence, and focused on delivering industrialised, scalable manufacturing. With Constellation, we are bringing a new, factory-led, fully-integrated automation approach to an industry that must scale to meet growing patient demand.”

Mark Leech, Mergers and Acquisitions Director at Bruntwood SciTech: “This landmark deal with Cellular Origins reflects our ambition for Melbourn Science Park – bringing together pioneering, innovation-led businesses with access to world-leading research and talent to help them scale in the UK. Having worked closely with the team throughout this process, we’re excited by the pace of their growth, the scale of their plans and their confidence in the Park to support their next phase.

“Melbourn Science Park has a strong track record of supporting some of the most exciting science and technology businesses. Its combination of high-quality facilities and a collaborative, wellbeing-focused environment – alongside access to Bruntwood SciTech’s UK-wide ecosystem of partners, talent and innovation-led companies – creates the conditions for businesses and their people to grow and thrive, particularly in high-growth areas such as advanced therapies and life sciences.”

As part of the wider Bruntwood SciTech community, customers at Melbourn Science Park also benefit from access to its UK-wide ecosystem of over 1,450 innovation-focused companies, alongside strategic partnerships with universities and research institutions, providing pathways to clinical collaboration and access to a highly skilled research base and workforce.